Member Info for mrdigit

Staircase? I think we are taking the elevator at the moment! Hopefully the elevator back up before long

This how they work it, how markets are made, draw you in, fear and doubt, then spit you out, by taking it back up and counting their cash

Fundamentals here? Incredible (as been said many times)
Patience will be rewarded

Millionaires have recently put millions into Sareum at prices considerably higher than today

I’ll leave it at that

Webbs, ha! filtered a long time ago, talks rubbish, changes mind with the wind, and I remember had this thing about being the first to post each morning on or just before the bell, with nothing really to say, complete Nonsense

For many it’s a case of…watch and learn

Ha, was just going to post that. A nice summary of the fantastic position we are in

Munchbox, everything you said there is utter rubbish, I hope no one new to OMI and it’s amazing position and prospects take notice of that drivel

Orosur CEO Brad George commented:

"The decision by our partners to take over operatorship of Anzá was both positive and welcome, being testament to how two of the world's largest gold miners see the region. The handover process is substantially complete. The financial and technical resources that can now be brought to bear are without parallel and we look forward to them substantially ramping up activity."

Hope you don't mind Brighty1 if i re-post one of yours from last night, which i think sums up where we are nicely, and why there should excitement in anticipation that something big is coming in for Sareum and it's holders....

Most of what has happened over the last 18 months has been about getting ones "ducks in a row" for licencing and or a takeover.
* Global Patents all sorted = Significant IP Value creation.
* HNWI's onboard investing £4.5million = avoids a suitor offering a cheap price. "We don't need your money. Come back when you have a real deal for us to review".
* Appointment of a heavyweight Joint Corporate Broker = deal maker
* UKRI Covid announcement that our profile was superior to Dexamethasone and similar to Baricitinib = indisputable credibility of the Sareum science
* Edison Open House = HNWI investment rather than traditional placings / dilution.
We are ready to Rock and Roll in other words. Have a great evening.
Good luck, Brighty

I think it’s worth mentioning the age of Tim and co, they will be looking for a nice retirement, and I’m sure they will want to take a very large pay check sooner rather than later to enjoy that well deserved retirement.

It’s so blatantly obvious from watching these boards for years, and especially the Sareum board this past year, that there are good things to come soon. The likes of KoolKat bash away as the price diminishes, then we get news to lift the price, and they are gone, no where to be seen, not a single post, then as the price begins to drift for some time, and reaches a worrying point for some (especially new) investors, in they come, more and more of them. News lands, up we go, gone are they, and on to the next lettuce hand victims. Aim, oh what a joy lol

Well Strean, i would say that the share price over those years has gone from 0.2p to 9p, patience from anywhere near the low to high would be a handsome reward, and so will it be in the future when we rise from here to the next level on transformational news on one of many gems

If they had any doubts, they quite simply might want consider the reason why multiple HNWI have recently put millions in our company...much better connected people than us...just a thought!

Dr Tim Mitchell, CEO of Sareum, commented:

"Sareum continues to advance the preclinical development of its proprietary dual TYK2/JAK1 inhibitor programmes. We are close to completing the preclinical development of SDC-1801 with the aim of starting the clinical development of this novel compound in the second half of 2022. This is clearly a very important milestone for the Company. In addition, the early preclinical results we have seen with SDC-1801 in our Covid-19 programme suggest that it may have potential to address the hyper-inflammatory response that some patients experience, and we are looking at the next steps to advance development in this indication. We are particularly pleased to have raised substantial additional funding that will be deployed to advance these programmes into clinical development and build a robust data package that will add momentum to our ongoing partnering activities for these exciting and differentiated assets.

"Furthermore, the possibility that clinical combination studies of SRA737 could be initiated by Sierra in the first half of 2022 is very encouraging and would represent a significant advance in the development of the SRA737 programme. We look forward to further updates on the clinical development of this candidate as the programme progresses."

waning immunity and booster vaccination stalling, as our infection and death rate in the UK is rising, far above many other European countries.....come on SAR, you seeminly have the answer, let's see you make history!

Wishing you you well Notalot. You got this!

Any historical RNS’s, and when one drops, there will be nothing on here currently, so best to use other sources for that for now

STILL technical issues on this site, no RNS details etc. Terrible!

Still no RNS info available on any share? Come on LSE tech team, there is no way I would pay for any service on here with these issues happening on a regular basis!

Back up and running at last, this is becoming a regular occurrence, very poor for a site like this... sort it out LSE!